Palladio Biosciences, Inc., is a Centessa company. Our first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.